Related Experiment Videos
Newer neuromuscular blocking agents: how do they compare with established agents?
H J Sparr1, T M Beaufort, T Fuchs-Buder
1Department of Anaesthesiology and Critical Care Medicine, The Leopold-Franzens-University of Innsbruck, Austria. harald.j.sparr@uibk.ac.at
Drugs
|July 4, 2001
Summary
Rapacuronium, rocuronium, and cisatracurium are neuromuscular blocking agents (NMBAs) used in anesthesia. Rapacuronium offers rapid onset but has dose-related adverse effects, while rocuronium provides good intubating conditions. Cisatracurium is a potent NMBA with slower onset but predictable recovery.
Area of Science:
- Anesthesiology
- Pharmacology
- Critical Care Medicine
Background:
- Neuromuscular blocking agents (NMBAs) are crucial for facilitating endotracheal intubation and surgical procedures.
- Rapacuronium bromide, rocuronium bromide, and cisatracurium besilate represent distinct options within the NMBA class, each with unique pharmacokinetic and pharmacodynamic profiles.
- Understanding their efficacy, onset, duration, and adverse effects is vital for optimal clinical application.
Purpose of the Study:
- To compare the clinical utility of rapacuronium bromide, rocuronium bromide, and cisatracurium besilate for tracheal intubation and neuromuscular blockade.
- To evaluate the onset of action, duration, and recovery characteristics of these NMBAs.
- To assess the safety profiles, including dose-related adverse effects and histamine release potential.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic data for rapacuronium, rocuronium, and cisatracurium.
- Analysis of clinical studies assessing intubating conditions and neuromuscular block.
- Comparison of adverse event profiles, including cardiovascular and respiratory effects.
Main Results:
- Rapacuronium offers rapid onset but has dose-dependent adverse effects (tachycardia, hypotension, bronchospasm), particularly in rapid-sequence induction. Its metabolite may delay recovery.
- Rocuronium provides rapid onset and good intubating conditions, with potential utility in rapid-sequence induction, though its long duration can be a concern in difficult intubations.
- Cisatracurium is a potent NMBA with a slower onset than atracurium but predictable recovery, independent of dose or infusion duration, and does not cause histamine release.
Conclusions:
- Rapacuronium may be suitable for short procedures but requires careful dosing (< or = 1.5 mg/kg) and is less ideal for rapid-sequence induction compared to succinylcholine or rocuronium.
- Rocuronium is a viable option for rapid sequence induction, especially with larger doses, offering an alternative to succinylcholine in cases of anticipated difficult intubation.
- Cisatracurium is a safe and effective NMBA, particularly useful when histamine release is a concern and predictable recovery is desired, though its onset is slower than some alternatives.